Description:
A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal
melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic
Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations
will be added to a standard therapy chosen by the tumor board (either checkpoint blockade or
chemotherapy).
Title
- Brief Title: IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
- Official Title: Phase I Vaccination Trial in Metastatic Uveal Melanoma Using IKKb-matured Dendritic Cells Loaded With Autologous Tumor-RNA + RNA Coding for Defined Antigens and Driver Mutations
Clinical Trial IDs
- ORG STUDY ID:
DERMA-ER-DC 09
- NCT ID:
NCT04335890
Conditions
- Melanoma, Uveal Metastatic
Interventions
Drug | Synonyms | Arms |
---|
Vaccination with IKKb matured Dendritic Cells | Dendritic Cell vaccine | DC IKKb |
Purpose
A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal
melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic
Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations
will be added to a standard therapy chosen by the tumor board (either checkpoint blockade or
chemotherapy).
Detailed Description
Intravenous infusion of 7.5 to 30 mio DCIKKb at 9 vaccination time points (week 1, 3, 7, 13,
19, 25, 31, 37 and 42) and in intervals of 2, 4, and 6 intervals of 6 weeks) is scheduled;
the first 4 patients will receive reduced doses for the first 4 vaccinations, namely 7.5 mio
(1st and 2nd vaccination) and 15 mio (3rd and 4th vaccination) DC followed by the full dose
of 30 mio for subsequent vaccinations. Patients number 5 to 8 will receive initially reduced
doses of 15 mio (1st and 2nd vaccination) DC for the first 2 vaccinations, and the full dose
of 30 mio for subsequent vaccinations. Patients number 8 to 12 will receive the full dose of
30 mio cells from vaccination 1 onwards provided that no major side effects occurred.
Patients will be vaccinated in a staggered approach by selectively decelerating release of
the vaccine.
DCIKKb = autologous, monocyte-derived DC that are matured with the standard cocktail
(TNF-alpha, IL-1 beta, IL-6 and PGE2) and IKKb-RNA loaded by electroporation with 1)
autologous PCR-amplified total tumor mRNA, 2) RNA coding for defined tumor associated
antigens (TAA) namely gp100, tyrosinase, PRAME, MAGE-A3, IDO) and 3) RNA coding for driver
mutations (GNAQ/GNA11Q209 or R183, or the less frequently occurring SF3B1R625, CYSLTR2L129Q
or PLCB4D630) by electroporation; RNAs for selected TAAs are in stock and will be transfected
into the DCs only if expressed in the individual tumor of a patient (shown by RNA sequencing
of the tumor); RNAs for selected driver mutations are in stock and will be loaded into the
DCs only if the respective mutation is found (proven by exome and RNA sequencing) in the
individual tumor.
Trial Arms
Name | Type | Description | Interventions |
---|
DC IKKb | Experimental | Vaccination with IKKb matured RNA loaded Dendritic Cells | - Vaccination with IKKb matured Dendritic Cells
|
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed unresectable stage IV metastatic uveal melanoma as per AJCC
staging system 2014, 7th edition (updated 2018) not curable with local therapy
modalities
- WHO performance status of 0, 1 or 2
- age from 18 and ≤ 75 years
- negative pregnancy test
- signed informed consent
Exclusion Criteria:
- Major serious illness
- evidence for HIV-1, HIV-2, HTLV-1, HBV or HCV infection
- active autoimmune disease requiring immunosuppressive therapy
- splenectomy or radiation therapy of the spleen
- organ allografts
- pregnancy
- lactation
- psychiatric disorders
- severe organic brain syndrome
Maximum Eligible Age: | 75 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Safety of DCIKKb |
Time Frame: | 1 year |
Safety Issue: | |
Description: | Assesment of side effects using the Common Toxicity Criteria (CTC v4.0) |
Secondary Outcome Measures
Measure: | Prolongation of median overall survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Assesment of survival |
Measure: | Prolongation of overall survival (OS) after 1 and 2 years |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Assesment of survival |
Measure: | Induction of antigen specific CD8+ T cells and / or CD4+ T cells against TAA and mutated drivers |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Assesment of immune responses |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Hasumi International Research Foundation |
Trial Keywords
- local treatment not sufficient
- systemic treatment indicated
Last Updated
November 6, 2020